Inactivated trivalent influenza vaccine (surface antigen), adjuvanted

PBAC's latest decision on Inactivated trivalent influenza vaccine (surface antigen), adjuvanted: Recommended (2018). Considered for Active immunisation against influenza in adults aged ≥65 years of age for prevention of seasonal influenza.

Eligible population

Adults aged ≥65 years of age eligible for free influenza vaccines through the NIP for prevention of seasonal influenza.

Therapy area

Vaccines

Line of therapy

Not applicable

Evidence base

RCT

Primary endpoint

Immunogenicity

Key trials

V70_27

Comparator

quadrivalent inactivated influenza vaccines (QIV) — Afluria Quad, FluQuadri, Fluarix Tetra

Economic model

Cost-minimisation

ICER note

Cost-minimisation analysis (CMA); no ICER calculated by design. Proposed price equal to nationally negotiated price of QIV comparator.

Similar precedents

• Influenza vaccine, adjuvanted quadrivalent and adjuvanted trivalent
  similarity 0.90
• Influenza vaccine, adjuvanted
  similarity 0.88
• Inactivated trivalent influenza vaccine (split virion)
  similarity 0.88
• Inactivated trivalent influenza vaccine (split virion), high dose
  similarity 0.83
• Inactivated quadrivalent influenza vaccine
  similarity 0.82
• Quadrivalent recombinant influenza vaccine
  similarity 0.80